Tag Archives: Federal Institute for Drugs and Medical Devices

International Meeting of Regulators on Challenges of Dementia Research and Drug Development (MHRA / Department of Health)

Posted on May 26, 2015 by Dementia and Elderly Care News

Summary The Medicines and Healthcare Products Regulatory Agency (MHRA) took part in an international workshop with other regulators, and has released a statement of intent about how to support the development of drugs for dementia. This work is in support … Continue reading →

Posted in Department of Health, For Doctors (mostly), For Researchers (mostly), International, Pharmacological Treatments, Quick Insights, World Health Organization (WHO) | Tagged Accelerating Alzheimer's Research and Drug Development, Attrition Analysis, Bill and Melinda Gates Foundation, Clinical Trial Efficiency, Composite End Points: Development of Standardised and Validated Endpoint Components, Coordinated Regulatory Action, Danish Health and Medicines Authority, Dementia Research, Department of Health’s Integrated Development Initiative, Disease Modifying Treatment by 2025 (Aim), Disease-Modifying Therapies, Disease-Modifying Therapies for Dementia, Drug Development for Alzheimer's Disease, Drug Regulation, Drug-Development Pipeline, European Medicines Agency, Expediting Regulatory Approval Procedures: Balancing Benefits and Risks, Federal Institute for Drugs and Medical Devices, First Global Ministerial Conference on Global Action Against Dementia, First WHO Ministerial Conference on Global Action Against Dementia, G7 Global Dementia Summit, G8 Dementia Summit, Global Alzheimer’s and Dementia Action Alliance (GADAA), Global Leadership, Global Ministerial Conference on Global Action Against Dementia (WHO), Global Outlook, Global Regulatory Efficiency and Consistency, Health Canada, Incentives, Incentives for Drug Development, International Federation of Pharmaceutical Manufacturers and Associations, Italian Medicines Agency, Market Failure (Dementia Research and Drug Development), Medicines and Healthcare Products Regulatory Agency, Medicines and Healthcare Products Regulatory Agency (MHRA), Medicines Evaluation Board, Multilateral Cooperation: Reducing Unnecessary Testing Replication and Methodology Testing, Office for Life Sciences, Pharmaceutical and Medicines Devices Agency (Japan), Pharmaceutical Regulators, Raj Long: Senior Regulatory Officer for Integrated Development in Global Health at the Bill & Melinda Gates Foundation, Regulation, Regulators, Regulatory Barriers, Regulatory Research Dementia Workshop, Regulatory System, Removing Regulatory Barriers, Research and Innovation, Resource and Incentives, Swissmedic, Translational Research, US Food and Drug Administration, WDC: World Dementia Council, WHO: World Health Organization, World Dementia Council | Leave a comment

Tag Archives: Federal Institute for Drugs and Medical Devices

International Meeting of Regulators on Challenges of Dementia Research and Drug Development (MHRA / Department of Health)

Recent Posts

Archives

Categories

Google Translate (100+ Languages)

Recommended Sites